HMN-154

Research use only, not for human use.

HMN-154 is a novel benzenesulfonamide anticancer compound.

HMN-154 is a benzenesulfonamide anticancer agent. HMN-154 inhibits DNA binding of NF-Y to the human major histocompatibility complex class II human leukocyte antigen DRA Y-box sequence in a dose-dependent manner.

HMN-154 interacts with NF-YB and thereby interrupts the binding of the NF-Y heterotrimer to DNA. NF-YB and thymosin β-10 are specific cellular binding proteins of HMN-154 and that this shared region is necessary for the binding to HMN-154. HMN-154 inhibits DNA binding of NF-Y to the human major histocompatibility complex class II human leukocyte antigen DRA Y-box sequence in a dose-dependent manner. HMN-154 shows very strong cytotoxicity against KB and colon38 cells with an IC50 value of 0.0026 and 0.003 μg/mL, respectively. HMN-154/BSA binds recombinant NF-YB or thymosin β-10 and the binding is inhibited by the addition of HMN-154 as the competitor. The binding between HMN-154 and NF-YB is specific and depends on its cytotoxicity.

——

HMN-154 | HMN 154 | HMN154

Tyrosine Kinase

TAM Receptor

Others

Cancer

——

173528-92-2

366.44

C20H18N2O3S

>98% (HPLC)

In Vitro:?DMSO : ≥ 15 mg/mL (40.94 mM)

c1(c(cccc1)/C=C/c1ccncc1)NS(=O)(=O)c1ccc(cc1)OC

(E)-4-(2-(2-(N-(4-Methoxybenzenesulfonyl)amino)phenyl)ethenyl)pyridine

(-20℃)

With Ice Pack

≥ 2 years